Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC: A Single Arm, Phase II Clinical Study

NCT07050056 is registered in ClinicalTrials.gov with Northern Jiangsu People's Hospital as lead sponsor.

NCT NCT07050056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07050056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC: A Single Arm, Phase II Clinical Study
Lead sponsor
Northern Jiangsu People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable nsclc